Twist Bioscience Reports Monday With Breakeven Timeline Now Three Quarters Away

Twist Bioscience Corp (TWST) reports fiscal third-quarter earnings before market open on Monday, August 3, with investors scrutinizing whether the synthetic DNA maker can sustain its trajectory toward profitability after shares surged 154% over the past year. The central question: can management demonstrate continued momentum in DNA synthesis and protein solutions while narrowing losses, or will valuation concerns that prompted recent downgrades prove justified? With the stock trading near analyst price targets after a sharp rally, this report will test whether TWST's positioning as an AI-enabled drug discovery beneficiary can support current levels.

Part 1: Earnings Preview

Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using its proprietary silicon platform, serving customers in pharmaceutical development, agricultural biotechnology, and industrial chemicals. The company's DNA synthesis and protein solutions businesses have driven consistent revenue growth as demand expands for precision genomics tools.

TWST is expected to report fiscal Q3 results before market open on August 3, 2026. Analysts forecast a loss of $0.50 per share on revenue of approximately $114.6 million. The company most recently reported Q2 earnings of $-0.62 per share, missing estimates by $0.08. Compared to the same quarter last year when TWST posted $-0.47 per share, the current estimate represents a 6.4% deterioration year-over-year, though revenue is projected to climb 19% from prior-year levels.

Three key themes define this earnings story:

Path to Profitability: Management's May analyst day highlighted improving unit economics and operating leverage, but recent quarters have shown widening losses despite revenue growth. Investors will scrutinize whether TWST can demonstrate tangible progress toward breakeven or if the profitability timeline is extending further.

AI-Driven Demand Acceleration: The company has positioned itself as a critical infrastructure provider for AI-enabled drug discovery, with management emphasizing growing demand from pharmaceutical customers using computational methods. Evidence of accelerating order flow or expanding partnerships in this segment would validate the investment thesis driving the stock's rally.

Valuation Sustainability: After shares more than doubled, Evercore ISI downgraded TWST to Hold in early July citing valuation concerns, even as other firms including Canaccord and Baird raised price targets to $120 and $113 respectively. The earnings report must justify current levels with either better-than-expected results or guidance that supports premium multiples.

Wall Street maintains a bullish stance overall, with a mean price target of $104 among 11 analysts implying modest upside from current levels. However, the recent flurry of raised targets followed by a high-profile downgrade suggests the Street is recalibrating expectations after the sharp appreciation. Analysts note that EPS estimates have risen 63% over the past 60 days, reflecting improved confidence in the business trajectory, though estimates have stabilized in recent weeks as the consensus view has solidified around the company's near-term outlook.

Part 2: Historical Earnings Performance

Twist Bioscience has delivered mixed results over the past four quarters, with two beats and two misses against consensus estimates. The company's earnings surprises have ranged from +12.96% in Q3 2025 to -14.81% most recently in Q2 2026, showing significant volatility in execution relative to expectations.

The trend reveals deteriorating performance in recent quarters. After beating estimates by nearly 13% a year ago, TWST has missed in three of the past four reports, including the most recent quarter's 14.81% shortfall. The Q2 2026 miss was particularly notable as the company reported $-0.62 versus the $-0.54 estimate, representing the widest negative surprise in the recent period.

This pattern suggests analysts may be struggling to model the company's path to profitability accurately, with estimates potentially too optimistic relative to the operational reality of scaling the business. The inconsistency in earnings performance—swinging from double-digit beats to double-digit misses—indicates execution challenges or visibility issues that make quarterly results difficult to predict with precision.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Twist Bioscience typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action around TWST earnings shows substantial volatility, with an average absolute Day 0 move of 10.23% and Day +1 follow-through averaging 3.55%. The stock has demonstrated a bearish bias in immediate reactions, with five of the past eight Day 0 moves negative, including three declines exceeding 10%.

The most extreme reaction came in August 2024, when shares plunged 19.00% on Day 0 before recovering 5.49% the following session—a pattern suggesting initial overreactions that partially reverse. More recently, the May 2026 report triggered a 6.97% Day 0 decline with minimal follow-through, while February 2026 saw a sharp 13.98% Day 0 rally that gave back ground on Day +1.

The wide Day 0 trading ranges—averaging 12.25%—reflect high uncertainty and active repositioning as investors digest results. Day +1 ranges remain elevated at 10.14%, indicating continued volatility extends beyond the initial reaction. Investors should prepare for significant price swings in both directions, with historical precedent suggesting moves of 10% or more are common regardless of whether results beat or miss estimates.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.75% for the August expiration, significantly higher than the stock's average historical Day 0 move of 10.23%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction to this earnings report, potentially reflecting heightened uncertainty around valuation sustainability after the stock's 154% rally or increased stakes around management's profitability guidance.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Twist Bioscience with an average rating of 4.64 (Strong Buy territory) and a mean price target of $104.00, implying approximately 13.6% upside from the current price of $91.55. The consensus includes 9 Strong Buy ratings, 0 Moderate Buys, and 2 Hold ratings, with no sell recommendations.

However, sentiment has deteriorated over the past month, with the average recommendation slipping from 4.82 as one analyst downgraded from Strong Buy to Hold. This shift reflects growing caution about valuation after the stock's sharp appreciation, even as the broader analyst community remains constructive on the long-term opportunity.

Price targets span a wide range from $85 to $120, with the high-end estimate from Canaccord representing 31% upside and suggesting some analysts see significant additional appreciation potential if the company can demonstrate accelerating progress toward profitability. The mean target of $104 sits comfortably above current levels but below the most optimistic forecasts, indicating the Street sees modest near-term upside with execution risk balanced against the company's positioning in high-growth synthetic biology markets.

Part 4: Technical Picture

Twist Bioscience enters earnings with strong technical momentum, as the Barchart Technical Opinion registers a 96% Buy signal, up from 88% one week ago and down slightly from 100% one month ago. This elevated reading reflects robust near-term momentum despite the stock trading near recent highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings event
• Medium-term (100% Buy): Sustained strength across the intermediate timeframe confirms the uptrend remains intact
• Long-term (100% Buy): Maximum long-term buy signal reflects the stock's transformation from a $52 level six months ago to current levels

Strong Strongest trend characteristics indicate TWST is exhibiting maximum momentum across all timeframes, creating an environment where the stock enters earnings with significant technical support but also elevated expectations that results must meet to sustain the rally.

The stock is trading at $91.55, positioned above all major moving averages including the 5-day ($88.69), 20-day ($91.44), 50-day ($83.51), 100-day ($67.90), and 200-day ($52.58). This alignment with the current price sitting just above the 20-day average suggests the stock is testing resistance at recent highs while maintaining support from rising intermediate and long-term trend lines. The technical setup is supportive heading into earnings, but the proximity to the 20-day moving average and the stock's extended position above longer-term averages creates a scenario where a disappointment could trigger profit-taking, while a beat might struggle to generate significant upside given the already-stretched valuation and recent rally. Key support on any pullback would likely emerge at the 50-day moving average around $83.50, while a breakout above $92 would target the $104 analyst consensus price target.